<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28591317</article-id><article-id pub-id-type="pmc">5444883</article-id><article-id pub-id-type="doi">10.5935/abc.20170061</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Challenges of Translational Science</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>Leonardo R.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Polegato</surname><given-names>Bertha F.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Zornoff</surname><given-names>Leonardo A. M.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="c1"/></contrib><aff id="aff1">Departamento de Cl&#x000ed;nica M&#x000e9;dica - Faculdade de Medicina
de Botucatu, Botucatu, SP - Brazil</aff></contrib-group><author-notes><corresp id="c1"><bold>Mailing Address: Leonardo A. M. Zornoff</bold>, Departamento
de Cl&#x000ed;nica M&#x000e9;dica, Faculdade de Medicina de Botucatu - Av. Prof.
M&#x000e1;rio Rubens Guimar&#x000e3;es Montenegro, s/n. Postal Code 18618-687,
UNESP - Campus de Botucatu, Botucatu, SP - Brazil. E-mail:
<email>lzornoff@fmb.unesp.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>5</month><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>5</month><year>2017</year></pub-date><volume>108</volume><issue>5</issue><fpage>388</fpage><lpage>389</lpage><history><date date-type="received"><day>07</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>12</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><kwd-group><kwd>Animal Models</kwd><kwd>Ischemia-reperfusion injury</kwd><kwd>Myocardial Infarction</kwd><kwd>Signaling Pathways</kwd></kwd-group></article-meta></front><body><p>The introduction of standardized therapies for the treatment of major cardiovascular
diseases, such as heart failure and myocardial infarction, significantly reduced
mortality. However, cardiovascular diseases are still one of the main causes of
morbidity and mortality worldwide. Consequently, a large number of experimental studies
are published regarding this subject. These studies investigate, in addition to the
mechanisms involved in the genesis of cardiovascular disease, potential therapeutic
targets, as well as interventions that are beneficial in reducing the size of the
ischemic lesion and the progression of cardiac dysfunction and, consequently, decrease
mortality.</p><p>In some situations, the results of preclinical research are reproducible in clinical
studies. As an example, we could cite the influence of obesity on the process of cardiac
remodeling. It is accepted that the remodeling process plays a critical role in the
onset and progression of cardiac dysfunction secondary to different stimuli.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> Experimental studies have shown that
obesity induces ventricular remodeling,<sup><xref rid="r2" ref-type="bibr">2</xref></sup> since it has been confirmed in clinical studies.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup></p><p>However, not infrequently, the success of the experimental treatments studied does not
replicate when applied to clinical studies. In this sense, the analysis of some recently
published papers in the <italic>Arquivos Brasileiros de Cardiologia</italic>, in the
field of basic / experimental research exemplifies this phenomenon.</p><p>One of the most interesting topics in cardiology today are the strategies to attenuate
ischemia / reperfusion injury (RI). Thus, in the rat model, hypothyroidism, associated
with decreased levels of nitric oxide, protected the heart from IR injury. Similarly,
physical exercise,<sup><xref rid="r6" ref-type="bibr">6</xref></sup> administration of
tramadol<sup><xref rid="r7" ref-type="bibr">7</xref></sup> and consumption of
nitrate<sup><xref rid="r8" ref-type="bibr">8</xref></sup> were effective in
decreasing IR-induced injury in the rat model. These and other positive results from
experimental studies are obfuscated by the fact that to date, cardioprotection
strategies in clinical studies have shown negative results.<sup><xref rid="r9" ref-type="bibr">9</xref></sup></p><p>The reasons for this frustrating inconsistency between experimental and clinical studies
are many and reflect the full complexity of translational research. The first difficulty
that can be pointed out is in relation to the animals used in the experimental studies.
We can observe that much of the research uses small animals, usually rodents, as the
target of the intervention. It is well known that the physiology of the cardiovascular
system of small rodents is not necessarily the same as that of humans. High heart rate
and differences in cellular ion fluxes, including calcium flux, do not allow the
extrapolation of the results of these studies to humans. In addition, small rodents used
in laboratories are genetically very homogeneous and, in some situations, are virtually
the same.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> Although the experimental
model with large animals is more similar to human and large animals are genetically more
heterogeneous, research involving models with larger animals is much more difficult to
conduct.</p><p>Another point to highlight is that most of the experimental studies use young and healthy
animals, which differs significantly from the reality of the patients included in the
clinical studies. It is not uncommon for patients with cardiovascular disease to have
more than one comorbidity. Even when comorbidities are inserted in the experimental
models, they are not treated, as is the case with patients.<sup><xref rid="r11" ref-type="bibr">11</xref></sup> Treatment of these comorbidities involves the use of
several medications, such as angiotensin converting enzyme inhibitors and beta-blockers,
which also exert a cardioprotective effect. Accordingly, some pathological modulating
pathways of pathological processes may already be blocked, even partially, by such
medications. Thus, the insertion of one more cardioprotective factor in clinical studies
may lead to very subtle improvements in outcomes, which are not statistically
significant. In addition, cardioprotection involves the activation of multifactorial
mechanisms and the presence of comorbidities and medications can modify the individual
panel of gene expression of patients.<sup><xref rid="r12" ref-type="bibr">12</xref></sup></p><p>We must also consider that the most common experimental model to study the
pathophysiological consequences of myocardial infarction is the external ligation of the
anterior descending artery, whereas in humans, coronary occlusion is the result of a
long inflammatory process. In this way, the activated signaling pathways can be
completely different. Even when models of ApoE knockout mice are used in the induction
of atherosclerosis, this happens in an artificial way and does not reproduce the reality
of what happens in humans.<sup><xref rid="r13" ref-type="bibr">13</xref></sup>
Additionally, lipid metabolism in mice is different, since in mice there is a
predominance of lipoprotein HDL, whereas in humans there is a predominance of LDL and
VLDL.<sup><xref rid="r13" ref-type="bibr">13</xref></sup></p><p>In addition, regarding the difficulties of reproducing experimental results in clinical
studies in myocardial infarction, in humans one of the pillars of the treatment is the
institution of reperfusion as soon as possible. This measure alone is already successful
in decreasing infarct size and mortality, and the beneficial effect of any additional
intervention can be minimized in clinical studies.<sup><xref rid="r14" ref-type="bibr">14</xref></sup></p><p>Another limitation of translational research is the transposition of the doses used in
animals to humans, as well as the time of onset and duration of treatment. The drug or
substance should achieve adequate concentration in the target tissue, while at the same
time it can not be excessive, because of the risks of side effects. As a consequence,
subtherapeutic doses may sometimes be used in clinical studies. An example of this is
the PREMIER study, which evaluated the effect of selective inhibitor of matrix
metalloproteinases PG 116800 in patients after myocardial infarction. In this study, due
to the risk of the onset of musculoskeletal syndrome, one of the side effects of the
administration of inhibitors of matrix metalloproteinases, a dose lower than that shown
to be effective in preclinical studies in pigs was used. Thus, despite promising
therapy, this study did not show any effect of PG 116800 on clinical outcomes.<sup><xref rid="r15" ref-type="bibr">15</xref></sup></p><p>Therefore, although the contributions of experimental research in the area of cardiology
are unquestionable, the challenge that remains is getting a greater transposition, in
the minimum of possible time, of the results obtained on the workbench to the clinical
practice.</p></body><back><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azevedo</surname><given-names>PS</given-names></name><name><surname>Polegato</surname><given-names>BF</given-names></name><name><surname>Minicucci</surname><given-names>MF</given-names></name><name><surname>Paiva</surname><given-names>SA</given-names></name><name><surname>Zornoff</surname><given-names>LA</given-names></name></person-group><article-title>Cardiac remodeling: concepts, clinical impact, pathophysiological
mechanisms and pharmacologic treatment</article-title><source>Arq Bras Cardiol</source><year>2016</year><volume>106</volume><issue>1</issue><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">26647721</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>F</given-names></name><name><surname>Campos</surname><given-names>DH</given-names></name><name><surname>Pagan</surname><given-names>LU</given-names></name><name><surname>Martinez</surname><given-names>PF</given-names></name><name><surname>Okoshi</surname><given-names>K</given-names></name><name><surname>Okoshi</surname><given-names>MP</given-names></name><etal/></person-group><article-title>High-fat diet promotes cardiac remodeling in an experimental
model of obesity</article-title><source>Arq Bras Cardiol</source><year>2015</year><volume>105</volume><issue>5</issue><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">26291841</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenchaiah</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>JC</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Obesity and the risk of heart failure</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><issue>5</issue><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">12151467</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abel</surname><given-names>ED</given-names></name><name><surname>Litwin</surname><given-names>SE</given-names></name><name><surname>Sweeney</surname><given-names>G</given-names></name></person-group><article-title>Cardiac remodeling in obesity</article-title><source>Physiol Rev</source><year>2008</year><volume>88</volume><issue>2</issue><fpage>389</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">18391168</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeddi</surname><given-names>S</given-names></name><name><surname>Zaman</surname><given-names>J</given-names></name><name><surname>Ghasemi</surname><given-names>A</given-names></name></person-group><article-title>Effects of ischemic postconditioning on the hemodynamic
parameters and heart nitric oxide levels of hypothyroid rats</article-title><source>Arq Bras Cardiol</source><year>2015</year><volume>104</volume><issue>2</issue><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">25424164</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>JP</given-names></name><name><surname>Lessa</surname><given-names>MA</given-names></name></person-group><article-title>mechanisms involved in exercise-induced cardioprotection: a
systematic review</article-title><source>Arq Bras Cardiol</source><year>2015</year><volume>105</volume><issue>1</issue><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">25830711</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takhtfooladi</surname><given-names>HA</given-names></name><name><surname>Asl</surname><given-names>AH</given-names></name><name><surname>Shahzamani</surname><given-names>M</given-names></name><name><surname>Takhtfooladi</surname><given-names>MA</given-names></name><name><surname>Allahverdi</surname><given-names>A</given-names></name><name><surname>Khansari</surname><given-names>M</given-names></name></person-group><article-title>Tramadol alleviates myocardial injury induced by acute hindlimb
ischemia reperfusion in rats</article-title><source>Arq Bras Cardiol</source><year>2015</year><volume>105</volume><issue>2</issue><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">26039663</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeddi</surname><given-names>S</given-names></name><name><surname>Khalifi</surname><given-names>S</given-names></name><name><surname>Ghanbari</surname><given-names>M</given-names></name><name><surname>Bageripour</surname><given-names>F</given-names></name><name><surname>Ghasemi</surname><given-names>A</given-names></name></person-group><article-title>Effects of nitrate intake on myocardial ischemia-reperfusion
injury in diabetic rats</article-title><source>Arq Bras Cardiol</source><year>2016</year><volume>107</volume><issue>4</issue><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">27849257</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Botker</surname><given-names>HE</given-names></name><name><surname>Engstrom</surname><given-names>T</given-names></name><name><surname>Erlinge</surname><given-names>D</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Ibanez</surname><given-names>B</given-names></name><etal/></person-group><article-title>Targeting reperfusion injury in patients with ST-segment
elevation myocardial infarction: trials and tribulations</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><issue>13</issue><fpage>935</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">27118196</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara-Pezzi</surname><given-names>E</given-names></name><name><surname>Menasch&#x000e9;</surname><given-names>P</given-names></name><name><surname>Trouvin</surname><given-names>JH</given-names></name><name><surname>Badim&#x000f3;n</surname><given-names>L</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Guidelines for translational research in heart
failure</article-title><source>J Cardiovasc Transl Res</source><year>2015</year><volume>8</volume><issue>1</issue><fpage>3</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">25604959</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Garcia-Dorado</surname><given-names>D</given-names></name><name><surname>Erik B&#x000f8;tker</surname><given-names>H</given-names></name><name><surname>Davidson</surname><given-names>SM</given-names></name><name><surname>Downey</surname><given-names>J</given-names></name><name><surname>Engel</surname><given-names>FB</given-names></name><etal/></person-group><article-title>Novel targets and future strategies for acute cardioprotection:
Position Paper of the European Society of Cardiology Working Group on
Cellular Biology of the Heart</article-title><source>Cardiovasc Res</source><year>2017</year><comment>in press</comment></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Barrabes</surname><given-names>JA</given-names></name><name><surname>B&#x000f8;tker</surname><given-names>HE</given-names></name><name><surname>Davidson</surname><given-names>SM</given-names></name><name><surname>Di Lisa</surname><given-names>F</given-names></name><name><surname>Downey</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ischaemic conditioning and targeting reperfusion injury: a 30
year voyage of discovery</article-title><source>Basic Res Cardiol</source><year>2016</year><volume>111</volume><issue>6</issue><fpage>70</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">27766474</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleissner</surname><given-names>CA</given-names></name></person-group><article-title>Translational atherosclerosis research: From experimental models
to coronary artery disease in humans</article-title><source>Atherosclerosis</source><year>2016</year><volume>248</volume><issue>5</issue><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">26999293</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name></person-group><article-title>The pathophysiology of acute myocardial infarction and strategies
of protection beyond reperfusion: a continual challenge</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><issue>11</issue><fpage>774</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">27354052</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinale</surname><given-names>FG</given-names></name></person-group><article-title>Myocardial matrix remodeling and the matrix metalloproteinases:
influence on cardiac form and function</article-title><source>Physiol Rev</source><year>2007</year><volume>87</volume><issue>4</issue><fpage>1285</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">17928585</pub-id></element-citation></ref></ref-list></back></article>